Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Remix Therapeutics in the transaction. Remix Therapeutics announced it closed its $60 million financing led by The Column Group. The...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Remix Therapeutics in the transaction. Remix Therapeutics (Remix), a clinical stage biotechnology company, announced it had entered into...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer advised Remix Therapeutics on the deal. Remix Therapeutics, a Massachusetts-based biotech company, announced its $70 million Series B financing which included participation from Surveyor, Foresite...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented Remix Therapeutics on the deal. Remix Therapeutics, a Massachusetts-based biotech company, announced its collaboration agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical...
You must be a Standard 1 Year member to access this content.
